Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152298 | 0.89 | OPRD1 (0.40) | BDKRB1OPRM1OPRK1OPRD1ESR1 | |
| SCHEMBL4146769 | 0.87 | OPRD1 (0.42) | BDKRB1OPRM1OPRK1OPRD1ESR1 | |
| SCHEMBL4145039 | 0.83 | BDKRB1 (0.41) | BDKRB1OPRD1ESR1ESR2 | |
| SCHEMBL4148508 | 0.81 | OPRD1 (0.41) | BDKRB1OPRM1OPRK1OPRD1ESR1 | |
| SCHEMBL4140540 | 0.80 | HTR6 (0.44) | BDKRB1OPRD1 | |
| SCHEMBL4157959 | 0.80 | OPRD1 (0.38) | BDKRB1OPRD1ESR1ESR2 | |
| SCHEMBL1724558 | 0.79 | BDKRB1 (0.43) | BDKRB1OPRD1ESR1ESR2 | |
| SCHEMBL6365663 | 0.78 | BDKRB1 (0.43) | BDKRB1OPRD1 | |
| SCHEMBL1724631 | 0.78 | BDKRB1 (0.43) | BDKRB1OPRD1 | |
| SCHEMBL4145771 | 0.78 | OPRD1 (0.45) | OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | BDKRB1 51/4885OPRM1 272/4885OPRK1 28/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | BDKRB1 51/4885OPRM1 272/4885OPRK1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.